Johnson & Johnson CFO on Strategic Innovations and Business Divestitures

Strategic Portfolio Management at Johnson & Johnson

• 🎯 Johnson & Johnson is undergoing a strategic shift to focus on higher-growth, higher-margin businesses, a process guided by rigorous portfolio management.
• 💡 The decision to spin off the orthopedics business aims to allow that division to focus solely on its market, potentially benefiting from organic growth or M&A.
• 🚀 This move aligns with CEO Wen Dato's vision to make J&J's medtech unit a global leader by concentrating on areas where the company truly thrives.

Rationale for Divesting Orthopedics

• 🧩 While the orthopedics business is profitable and supported by strong demographics, it faces competitors focused exclusively on that sector, creating a competitive disadvantage.
• 💰 The spin-off is structured as a publicly traded standalone company, though other avenues like a sale are being considered if they add value for shareholders.
• 📈 The company is prioritizing transformational innovation, which is less prevalent in established areas like hip and knee replacements compared to other J&J segments.

Capital Allocation and Future Investments

• 💰 Johnson & Johnson maintains a strong capital position with $20 billion in free cash flow and a AAA credit rating, enabling strategic acquisitions and portfolio pruning.
• 🏥 Future investments are targeted towards standout divisions in pharmaceuticals (oncology, immunology, neuroscience) and medtech (vision care, surgery, cardiovascular), evidenced by recent acquisitions like Abiomed and Shockwave.

Innovation in Pharmaceuticals and Medtech

• 🔬 J&J is committed to breakthrough innovation, investing 15-16% of sales (over $3.5 billion per quarter) in R&D, unaffected by external pressures on drug pricing.
• 💡 A novel bladder cancer treatment, involving a minimally invasive outpatient procedure with an 82% response rate, exemplifies J&J's focus on unmet medical needs.
• 👁️ New developments in contact lenses, such as the Acuvue Oasys 1-Day Max, address astigmatism and presbyopia, demonstrating continuous innovation in vision care.
• 🇺🇸 The company is also investing significantly in US-based manufacturing facilities for medtech and pharmaceuticals, creating high-tech, well-paying jobs.